Write a complete SOAP note for a patient presenting with slurred speech and weakness, with assessment of chronic kidney disease and rule out cerebrovascular accident.

SOAP Note: Acute Neurological Presentation with CKD

Subjective

• Chief Complaint: Slurred speech and weakness
• History of Present Illness: Patient presented with acute onset of slurred speech and generalized weakness. Duration, time of onset, and progression of symptoms need documentation. Critical to establish exact time of symptom onset for potential thrombolytic therapy window.
• Key Questions to Address:
  • Exact time symptoms began (critical for stroke protocol)
  • Progression pattern (sudden vs. gradual)
  • Associated symptoms: facial droop, vision changes, headache, confusion, nausea/vomiting
  • Recent medication changes, particularly diuretics or antihypertensives
  • Dialysis schedule if applicable
  • Recent illnesses or volume depletion

Objective

Vital Signs Required:

• Blood pressure (target <120 mmHg systolic per KDIGO for CKD patients) 1
• Heart rate and rhythm (assess for atrial fibrillation)
• Temperature, respiratory rate, oxygen saturation

Critical Physical Examination:

• NIH Stroke Scale score (document baseline severity)
• Facial symmetry and droop
• Motor strength in all extremities (quantify weakness)
• Speech assessment (dysarthria vs. aphasia)
• Cranial nerve examination
• Gait assessment if safe
• Volume status (orthostatic vitals, jugular venous pressure, edema)

Essential Laboratory Studies:

• Serum sodium (hyponatremia can mimic stroke) 2
• Complete metabolic panel including creatinine and eGFR
• Complete blood count (assess anemia, target Hgb 10-12 g/dL in CKD) 1
• Coagulation studies (PT/INR, aPTT)
• Troponin and BNP
• Lipid panel
• Hemoglobin A1c if diabetic
• Urine albumin-to-creatinine ratio (UACR) 3

Imaging:

• Non-contrast CT head (STAT to rule out hemorrhage)
• CT angiography head/neck (identify large vessel occlusion; contrast is acceptable in CKD for acute stroke evaluation) 4
• CT perfusion if thrombectomy candidate (benefits outweigh contrast risks) 4
• Consider MRI brain with DWI if diagnosis unclear

Assessment

1. Rule Out Acute Ischemic Stroke - HIGHEST PRIORITY

This is a stroke until proven otherwise. CKD patients have 40% increased stroke risk and worse outcomes 5, 6.

Immediate stroke protocol activation is mandatory - do not delay for CKD considerations 4.

2. Chronic Kidney Disease

• Document CKD stage based on eGFR and UACR 3, 7
• CKD is a stroke-equivalent cardiovascular risk 8
• Assess for diabetic kidney disease if applicable 9

3. Alternative Diagnoses to Exclude:

• Severe hyponatremia (can cause reversible stroke-like symptoms) 2
• Hypoglycemia
• Uremic encephalopathy
• Dialysis disequilibrium syndrome
• Posterior reversible encephalopathy syndrome (PRES)
• Seizure with Todd's paralysis

Plan

Acute Stroke Management (Time-Critical)

If Acute Ischemic Stroke Confirmed:

1. IV Thrombolysis (tPA):

   • Administer if within 4.5-hour window - CKD is NOT a contraindication 4
   • Standard dosing (0.9 mg/kg, max 90 mg)
   • Outcomes less robust than general population but still beneficial 4

2. Endovascular Thrombectomy:

   • Pursue if large vessel occlusion identified - CKD patients benefit from thrombectomy 4
   • Extended window protocols (up to 24 hours) apply to CKD patients
   • Contrast exposure justified by potential benefit 4

3. Blood Pressure Management:

   • Target systolic BP <120 mmHg per KDIGO guidelines 1
   • Use RAS blockers (ACE inhibitors or ARBs) as first-line agents 1
   • Avoid excessive BP lowering during acute stroke (permissive hypertension if thrombolysis not given)

Secondary Stroke Prevention (Once Acute Phase Managed)

1. Antiplatelet Therapy:

   • Initiate aspirin 81-325 mg daily for secondary prevention 1
   • Consider dual antiplatelet therapy (aspirin + clopidogrel) for 21-90 days if high-risk TIA or minor stroke
   • Antiplatelet therapy uniformly recommended by KDIGO/AHA/ASA for secondary prevention 1

2. Anticoagulation (if Atrial Fibrillation Present):

   • If eGFR >30 mL/min/1.73 m²: Use DOAC as first-line 1
   • If eGFR 15-29 mL/min/1.73 m²: Discuss with nephrology; choice depends on kidney function trajectory 1
   • If eGFR <15 mL/min/1.73 m² or on dialysis: Discuss with nephrology; consider DOAC or warfarin per AHA/ACC 1

3. Lipid Management:

   • Initiate statin therapy immediately - recommended for all CKD patients post-stroke 1
   • Use statin or statin/ezetimibe combination 1
   • If on dialysis and not already taking statin, only start if LDL-C >145 mg/dL 1

4. Carotid Evaluation:

   • Obtain carotid duplex ultrasound
   • Consider carotid revascularization only if symptomatic moderate-severe stenosis in non-dialysis CKD patients 1
   • Do NOT pursue routine revascularization for asymptomatic disease 1

CKD-Specific Management

1. Nephrology Consultation:

   • Refer to nephrology if:
     • eGFR <30 mL/min/1.73 m² 3
     • Rapidly declining kidney function
     • Uncertainty about CKD etiology 9
     • Need for dialysis planning

2. Optimize CKD Management:

   • Blood pressure control: Target systolic <120 mmHg with RAS blockers 1
   • Glycemic control if diabetic (A1c <7% generally) 9
   • SGLT2 inhibitor if diabetic and eGFR >30 mL/min/1.73 m² 1
   • Monitor serum creatinine and potassium when using RAS blockers 9
   • Protein intake 0.8 g/kg/day for non-dialysis CKD 3

3. Anemia Management:

   • Target hemoglobin 10-12 g/dL 1
   • Avoid over-correction which increases stroke risk

4. Volume and Dialysis Considerations:

   • Careful attention to volume control 1
   • If on dialysis: coordinate timing to avoid cerebral hypoperfusion during acute stroke period

Critical Pitfalls to Avoid

• Do NOT withhold thrombolysis or thrombectomy due to CKD 4
• Do NOT avoid contrast imaging in acute stroke - benefits far outweigh AKI risk 4
• Do NOT delay stroke workup for metabolic correction unless severe hyponatremia is obvious cause 2
• Do NOT use antiplatelet therapy for primary prevention in CKD without clear indication 5
• Do NOT start statins de novo in dialysis patients unless LDL-C >145 mg/dL 1

Disposition

• Admit to stroke unit or ICU for monitoring
• Neurology consultation STAT
• Nephrology consultation within 24 hours
• Physical therapy, occupational therapy, speech therapy evaluations

Follow-up

• Repeat imaging at 24 hours post-thrombolysis if given
• Daily neurological assessments
• Monitor kidney function closely (contrast exposure, medication adjustments)
• Arrange outpatient neurology and nephrology follow-up